MILAN, Italy, July 2, 2002 (PRIMEZONE) -- BioXell SpA, the Italian biopharmaceutical company focused on immunology, today announced the appointment of Professor Bernd Seizinger to the Board of Directors.
Dr. Seizinger, currently President and Chief Executive Officer of GPC Biotech, having joined in 1998, has been responsible for leading the corporate development of the company from a private startup to a publicly traded transatlantic organisation. Prior to this, Dr. Seizinger spent 2 years as Executive Vice President and Chief Scientific Officer at Genome Therapeutics Corporation in Boston and 4 years as Vice President of Oncology Drug Discovery and Vice President of Corporate and Academic Alliances at Bristol Myers Squibb Pharmaceutical Research Institute.
In addition to his corporate appointments, Dr. Seizinger held positions as Director of the Molecular NeuroOncology Department at Massachusetts General Hospital and as Professor of Neuroscience at Harvard Medical School. Dr. Seizinger was awarded his M.D. from LudwigMaximilians University in Munich, Germany, and received his Ph.D. in Neurobiology from the Max Planck Institute of Psychiatry, Munich, Germany. Among his most notable accomplishments Dr Seizinger has been the recipient of a number of scientific awards and honors and has authored over one hundred publications.
Dr. Sinigaglia, Chief Executive Officer of BioXell said: "We are delighted that Dr Seizinger has joined the BioXell's Board of Directors. We welcome his considerable scientific, management and industry expertise, and look forward to his active role in the development of the Company."
Dr. Seizinger commented: "I am very pleased to be joining the Board of BioXell at this exciting time, as this young Company moves forward to the next stage. I look forward to contributing to its future success."
BioXell is a private research and development biopharmaceutical company with a competitive edge in immunology developing two strong technology platforms based on the TREM receptor system and Vitamin D3 analogues. From these, BioXell has identified molecules to be developed in secondary hyperparathyroidism, benign prostatic hyperplasia, as well as research programmes in inflammatory diseases such as asthma, psoriasis and rheumatoid arthritis. In March 2002, BioXell raised $22m in a firstround financing from a consortium of three toptier venture capital firms: MPM Capital, Index Ventures and Life Sciences Partners. BioXell has a network of academic collaborations, including Washington University, St. Louis and the Universities of Arkansas, Milan, Florence, Modena and Zurich. More information on BioXell can be found on: www.bioxell.com